Literature DB >> 33977921

In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics.

Axel Steinbrueck1, Adam C Sedgwick1, Hai-Hao Han2, Michael Y Zhao1, Sajal Sen1, Dan-Ying Huang1, Yi Zang3, Jia Li3, Xiao-Peng He2, Jonathan L Sessler1.   

Abstract

We report here strategic functionalization of the FDA approved chelator deferasirox (1) in an effort to produce organelle-targeting iron chelators with enhanced activity against A549 lung cancer cells. Derivative 8 was found to have improved antiproliferative activity relative to 1. Fluorescent cell imaging revealed that compound 8 preferentially localises within the lysosome.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33977921      PMCID： PMC8456774          DOI： 10.1039/d0cc08156f

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.065


  26 in total

Review 1.  Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease.

Authors:  Alexander R Bogdan; Masaki Miyazawa; Kazunori Hashimoto; Yoshiaki Tsuji
Journal:  Trends Biochem Sci       Date:  2015-12-23       Impact factor: 13.807

2.  The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.

Authors:  Sandrine Tury; Franck Assayag; Florian Bonin; Sophie Chateau-Joubert; Jean-Luc Servely; Sophie Vacher; Véronique Becette; Martial Caly; Audrey Rapinat; David Gentien; Pierre de la Grange; Anne Schnitzler; François Lallemand; Elisabetta Marangoni; Ivan Bièche; Céline Callens
Journal:  J Pathol       Date:  2018-08-07       Impact factor: 7.996

Review 3.  Iron chelation in the treatment of cancer: a new role for deferasirox?

Authors:  Matthew R Bedford; Samuel J Ford; Richard D Horniblow; Tariq H Iqbal; Chris Tselepis
Journal:  J Clin Pharmacol       Date:  2013-06-06       Impact factor: 3.126

4.  Synthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenes.

Authors:  Pascal Rouge; Alexandra Dassonville-Klimpt; Christine Cézard; Stéphanie Boudesocque; Roger Ourouda; Carole Amant; François Gaboriau; Isabelle Forfar; Jean Guillon; Emmanuel Guillon; Enguerran Vanquelef; Piotr Cieplak; François-Yves Dupradeau; Laurent Dupont; Pascal Sonnet
Journal:  Chempluschem       Date:  2012-11-01       Impact factor: 2.863

5.  The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.

Authors:  Goldie Y L Lui; Peyman Obeidy; Samuel J Ford; Chris Tselepis; Danae M Sharp; Patric J Jansson; Danuta S Kalinowski; Zaklina Kovacevic; David B Lovejoy; Des R Richardson
Journal:  Mol Pharmacol       Date:  2012-10-16       Impact factor: 4.436

Review 6.  Iron and cancer: more ore to be mined.

Authors:  Suzy V Torti; Frank M Torti
Journal:  Nat Rev Cancer       Date:  2013-04-18       Impact factor: 60.716

7.  Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.

Authors:  Samie Salehi; Amir Sh Saljooghi; Ali Shiri
Journal:  Eur J Pharmacol       Date:  2016-04-14       Impact factor: 4.432

8.  Salinomycin kills cancer stem cells by sequestering iron in lysosomes.

Authors:  Trang Thi Mai; Ahmed Hamaï; Antje Hienzsch; Tatiana Cañeque; Sebastian Müller; Julien Wicinski; Olivier Cabaud; Christine Leroy; Amandine David; Verónica Acevedo; Akihide Ryo; Christophe Ginestier; Daniel Birnbaum; Emmanuelle Charafe-Jauffret; Patrice Codogno; Maryam Mehrpour; Raphaël Rodriguez
Journal:  Nat Chem       Date:  2017-05-16       Impact factor: 24.427

Review 9.  Iron deprivation in cancer--potential therapeutic implications.

Authors:  Jessica L Heath; Joshua M Weiss; Catherine P Lavau; Daniel S Wechsler
Journal:  Nutrients       Date:  2013-07-24       Impact factor: 5.717

10.  Iron and Copper Intracellular Chelation as an Anticancer Drug Strategy.

Authors:  Kavita Gaur; Alexandra M Vázquez-Salgado; Geraldo Duran-Camacho; Irivette Dominguez-Martinez; Josué A Benjamín-Rivera; Lauren Fernández-Vega; Lesly Carmona Sarabia; Angelys Cruz García; Felipe Pérez-Deliz; José A Méndez Román; Melissa Vega-Cartagena; Sergio A Loza-Rosas; Xaymara Rodriguez Acevedo; Arthur D Tinoco
Journal:  Inorganics (Basel)       Date:  2018-11-30
View more
  2 in total

1.  2D-ultrathin MXene/DOXjade platform for iron chelation chemo-photothermal therapy.

Authors:  Yunjie Xu; Yingwei Wang; Jusung An; Adam C Sedgwick; Mingle Li; Jianlei Xie; Weibin Hu; Jianlong Kang; Sajal Sen; Axel Steinbrueck; Bin Zhang; Lijun Qiao; Swelm Wageh; Jonathan F Arambula; Liping Liu; Han Zhang; Jonathan L Sessler; Jong Seung Kim
Journal:  Bioact Mater       Date:  2021-12-18

2.  Dual-factor Synergistically Activated ESIPT-based Probe: Differential Fluorescence Signals to Simultaneously Detect α-Naphthyl Acetate and Acid α-Naphthyl Acetate Esterase.

Authors:  Kui Wang; Beidou Feng; Yonggang Yang; Yuehua Chen; Yuzhu Wang; Yafu Wang; Lin Yang; Kai Jiang; Tony D James; Hua Zhang
Journal:  Anal Chem       Date:  2021-10-24       Impact factor: 6.986
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.